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Oseltamivir has been widely used for pandemic (H1N1) 
2009 virus infection, and by April 30, 2010, a total of 285 
resistant cases were reported worldwide, including 45 in the 
United Kingdom. To determine risk factors for emergence 
of oseltamivir resistance and severe infection, a case–
control study was conducted in the United Kingdom. Study 
participants were hospitalized in England or Scotland 
during January 4, 2009–April 30, 2010. Controls had 
conﬁ  rmed oseltamivir-sensitive pandemic (H1N1) 2009 virus 
infections, and case-patients had conﬁ  rmed  oseltamivir-
resistant infections. Of 28 case-patients with available 
information, 21 (75%) were immunocompromised; 31 of 
33 case-patients (94%) received antiviral drugs before a 
sample was obtained. After adjusting for confounders, case-
patients remained signiﬁ   cantly more likely than controls 
to be immunocompromised and at higher risk for showing 
development of respiratory complications. Selective drug 
pressure likely explains the development of oseltamivir 
resistance, especially among immunocompromised patients. 
Monitoring of antiviral resistance is strongly recommended 
in this group.
N
euraminidase inhibitors, antiviral drugs that limit 
replication of inﬂ   uenza A and B viruses (1), are 
recommended in the United Kingdom for treatment 
and prophylaxis of patients at higher risk for severe or 
complicated inﬂ   uenza virus infection (2). During the 
initial containment phase of the 2009 inﬂ  uenza pandemic, 
antiviral drugs were prescribed for all patients with 
conﬁ   rmed infections and their close contacts. During 
the subsequent treatment phase of the pandemic, the 
drugs were recommended for persons with suspected 
inﬂ  uenza virus infections who were at high risk for severe 
disease (3).
Before the 2007–08 inﬂ  uenza season, the development 
of oseltamivir-resistant inﬂ   uenza was rare (4), mainly 
occurring among persons who were more likely to 
have prolonged virus shedding, such as children (5) and 
immunocompromised patients (6). Patients with subtype 
H1N1 oseltamivir-resistant strains had the same point 
mutation in the viral neuraminidase gene (H275Y) that is 
known to confer high-level resistance to oseltamivir (7), 
but the mutation was associated with reduced infectivity 
and replicative ability (8). During the 2007–08 season, 
transmissible inﬂ   uenza A (H1N1) viruses resistant to 
oseltamivir (with the H275Y mutation) emerged and became 
predominant over susceptible subtype H1N1 viruses (4,9). 
The inﬂ  uenza A pandemic (H1N1) 2009 virus was initially 
reported as fully susceptible to the neuraminidase inhibitors 
(oseltamivir and zanamivir) but resistant to adamantanes, 
having the S31N (serine to asparagine) mutation in the M2 
ion channel (10).
On July 8, 2009, the World Health Organization 
reported the ﬁ   rst sporadic cases of oseltamivir-resistant 
pandemic (H1N1) 2009 infection in Denmark; Japan; 
and Hong Kong Special Administrative Region, People’s 
Republic of China (11). By April 28, 2010, a total of 285 
oseltamivir-resistant cases had been reported worldwide 
(12), including 45 in the United Kingdom. Three clusters 
each were reported from Wales (13); the United Kingdom; 
North Carolina, USA (14); and Vietnam (15). All of the 
pandemic (H1N1) 2009 oseltamivir-resistant viruses had 
the previously described H275Y mutation. No reassortment 
between the pandemic (H1N1) 2009 virus and the seasonal 
oseltamivir-resistant subtype H1N1 inﬂ   uenza strain has 
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been detected (16–18), and all of the oseltamivir-resistant 
viruses have retained sensitivity to zanamivir.
This report describes the epidemiologic, clinical, and 
demographic characteristics of patients with oseltamivir-
resistant pandemic (H1N1) 2009 virus infections in England 
and Scotland. It also identiﬁ   es risk factors for severe 
infection and for the emergence of oseltamivir-resistant 
virus to inform modiﬁ  cations to current recommendations 
for the use of antiviral drugs for treatment and prophylaxis 
of inﬂ  uenza A pandemic (H1N1) 2009 virus infection.
Methods
Deﬁ  nition of Case-Patients and Controls
Case-patients were study participants who were 
hospitalized during January 4, 2009–April 30, 2010, with 
a conﬁ  rmed case of pandemic (H1N1) 2009 virus infection 
with the H275Y mutation in >50% of the virus quasispecies 
and/or oseltamivir resistance conﬁ  rmed by phenotyping of 
virus isolates. Controls were study participants who were 
hospitalized during January 4, 2009–April 30, 2010, with 
a conﬁ  rmed case of pandemic (H1N1) 2009 virus infection 
with no H275Y mutation detected in the virus.
Case Detection and Collection of 
Epidemiologic Information
In the United Kingdom, surveillance of antiviral 
susceptibility of inﬂ  uenza viruses was performed by the 
Respiratory Virus Unit (RVU), Health Protection Agency. 
Pandemic (H1N1) 2009 infection was diagnosed from 
respiratory specimens by real-time reverse transcription 
PCR. Regional laboratories refer to RVU specimens from 
hospitalized case-patients with laboratory-conﬁ  rmed 
pandemic (H1N1) 2009. The proportion referred is 
dependent on several factors. Emphasis is placed on the 
referral of positive specimens from early and late in the winter 
season and then a representative number during the peak 
inﬂ  uenza season. Laboratories are asked to refer equivocal 
specimens, specimens from patients with clinical antiviral 
treatment failure, and specimens from immunosuppressed 
patients and those who died. In addition, a proportion of 
community respiratory specimens from primary care 
clinics, selected to provide good regional coverage, were 
also tested for resistance. Selected specimens were tested 
by pyrosequencing of the neuraminidase gene to detect the 
presence of the H275Y mutation (19). The results were 
conﬁ  rmed whenever possible by culture and phenotyping 
of virus isolates. Phenotypic antiviral susceptibility was 
determined by neuraminidase enzyme inhibition assay, 
using a ﬂ  uorescent substrate as previously described (20). 
No patients with oseltamivir-resistant pandemic (H1N1) 
2009 viruses were identiﬁ   ed from Northern Ireland. A 
hospital cluster in Wales has been described separately 
(13). Therefore, this report only includes cases from 
England and Scotland.
For all reported cases of oseltamivir-resistant 
pandemic (H1N1) 2009 virus infection, epidemiologic data 
were gathered from the responsible clinician by the local 
Health Protection Unit or by Health Protection Scotland. 
The following patient information was collected by use of 
a standardized questionnaire: demographic details, clinical 
symptoms, complications, outcomes (hospitalization, 
admission to intensive care unit [ICU], death), underlying 
medical conditions (chronic respiratory, heart, neurologic, 
liver, renal diseases, diabetes, immunosuppression, 
pregnancy), and antiviral treatment.
Control Group
To identify risk factors for severe disease and for 
emergence of oseltamivir resistance, a reference control 
group was deﬁ  ned as hospitalized pandemic (H1N1) 2009 
case-patients with virologically conﬁ  rmed  oseltamivir-
sensitive infection. The control sampling frame was 
established by matching all virologically conﬁ  rmed 
oseltamivir-sensitive pandemic (H1N1) 2009 specimens 
diagnosed by the RVU to pandemic (H1N1) 2009 cases 
reported to a national hospital reporting system.
Through this hospital surveillance system, 
microbiologists recorded standardized data for all hospital 
inpatients in England with laboratory-conﬁ  rmed pandemic 
(H1N1) 2009 (21). Reports were made by 129 of the 160 
eligible hospital trusts in England. The dataset included 
demographic information, underlying medical conditions, 
antiviral treatment, complications, and information 
on outcome (ICU admission, death). On the basis of 
surname,  ﬁ   rst name, and date of birth, a probabilistic 
linkage was performed between the 2,817 subtype H1N1 
infections recorded in the hospital database and the 
3,479 oseltamivir-sensitive pandemic (H1N1) 2009 virus 
infections conﬁ  rmed during April 27, 2009–April 30, 2010 
(Figure). This method resulted in the selection of 346 study 
controls. Controls were pandemic (H1N1) 2009 patients 
infected with oseltamivir-sensitive viruses. All controls 
had been hospitalized in England and had available clinical 
information. Recommendations and clinical practice for 
hospitalization of pandemic (H1N1) 2009 patients were 
broadly similar in England and Scotland; thus, we assume 
that this reference group is representative of all pandemic 
(H1N1) 2009 patients hospitalized in England and Scotland.
Study Design and Statistical Analysis
To assess the representativeness of the case-patients 
whose specimens were tested for antiviral susceptibility and 
to identify any potential selection bias, our control group 
was compared with pandemic (H1N1) 2009 patients who 
were recorded in the hospital database as not having been 
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tested for antiviral susceptibility. To assess differences in 
distribution of possible risk factors (age, sex, underlying 
medical conditions) and outcomes, the χ2 or Fisher exact 
test for small numbers was used.
A case–control study was conducted to compare 
the hospitalized pandemic (H1N1) 2009 patients with 
oseltamivir-resistant virus infections with hospitalized 
pandemic (H1N1) 2009 patients with oseltamivir-sensitive 
virus infections in terms of underlying medical conditions 
and outcomes. To estimate the association between 
emergence of resistance and risk factors, we calculated 
crude odds ratios (ORs) and 95% conﬁ  dence  intervals 
(CIs). ORs were adjusted for possible confounders by using 
a step-up logistic regression model. For each variable, 
missing data were removed from the denominator. Data 
analysis was performed by using Stata version 11.0 
(StataCorp LP, College Station, TX, USA).
Ethical Approval
This study was conducted under National Health 
Service (NHS) Act 2006 (section 251), which provides 
statutory support for disclosure of such data by the NHS 
and their processing by the Health Protection Agency for 
the purposes of communicable disease control. Ethical 
approval was not required, and informed consent was not 
sought. Health Protection Scotland remains embedded 
as part of the NHS, in which the sharing of outbreak and 
investigation data are undertaken as part of their role in the 
coordination of national outbreaks.
Results
During April 27, 2009–April 30, 2010, RVU tested 
6,379 pandemic (H1N1) 2009 specimens for antiviral 
susceptibility (22). Among 3,515 pandemic (H1N1) 2009 
specimens sent by hospital laboratories in England and 
Scotland, 36 (1%) were oseltamivir resistant and 3,479 
(99%) were oseltamivir sensitive (Figure). All samples 
from primary care clinics were oseltamivir-sensitive.
For the 36 oseltamivir-resistant samples from case-
patients, the H275Y mutation was detected by pyrosequencing 
of the neuraminidase gene. The diagnosis was conﬁ  rmed by 
phenotyping for 13 of these patients (36.1%) but was not 
conﬁ  rmed by phenotypic typing for the remaining 23 patients 
due to unsuitable sample type (virus inactivated) or negative 
culture results. All 36 specimens remained sensitive to 
zanamivir. Oseltamivir-resistant (H275Y) quasispecies were 
detected in an additional 13 patients at proportions <50% 
(the specimen contained a mixture of virus variants, <50% 
of which harbored the mutation). These patients did not 
progress to having clinically relevant resistance, and none 
of the infections could be conﬁ  rmed phenotypically. For 
those patients who had further samples available, resistant 
quasispecies did not persist; thus, these 13 patients are not 
included further in this study.
Two of the 36 patients with an oseltamivir-resistant 
strain were not admitted to the hospital: both were 
immunosuppressed boys who had mild symptoms and 
recovered. For both patients, the resistant strain developed 
after antiviral treatment, and a pretreatment specimen 
(fully susceptible in 1 patient and with <50% of resistant 
quasispecies in the other) was available.
The remaining analyses relate to the 34 case-patients 
hospitalized with an oseltamivir-resistant infection who 
were included in the case-control study. Among these 
34 case-patients, 9 (26.5%) were from Scotland and 25 
(73.5%) were from England. Symptom onset of case-
patients ranged from June 25, 2009, to April 13, 2010, with 
3 of the 34 case-patients acquiring their infection during 
April 27–August 30, 2009, the spring/summer wave of the 
pandemic.
The 34 case-patients ranged in age from 4 months to 
95 years (median 52 years, mean 43.3 years) (Table 1); 
23 patients (67.6%) were male, and 11 (32.4%) were 
female (Table 1). Details of symptoms were available for 
22/34 case-patients (64.7%). The most common symptoms 
were cough (n = 20, 91.0%), fever (n = 17, 77.3%), and 
dyspnea (n = 12, 54.5%). Rhinorrhea, myalgia, headache, 
and fatigue were reported for 8 case-patients (36.4%) and 
gastrointestinal symptoms for 6 (27.3%). 
Of 25 case-patients with information available re-
garding complications, 21 (84.0%) reported complications: 
in 19 (76.0%), pneumonia or bronchitis developed, 1 (4.0%) 
had encephalitis, and 1 (4.0%) had acute renal failure 
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Figure. Flow chart showing testing of specimens from persons 
with conﬁ   rmed pandemic (H1N1) 2009 infection for antiviral 
susceptibility, United Kingdom, April 27, 2009–April 30, 2010.RESEARCH
related to secondary group A streptococcal infection. Of 
the 25 case-patients with available information, 12 (48.0%) 
were transferred to ICU for 6–31 days (mean 16.9 days, 
median 15 days).
Thirty case-patients had available information 
regarding underlying medical conditions, of whom 28 
(93.3%) had >1 underlying medical condition: 21 (75.0%) 
were immunosuppressed, 7 (25.0%) had a chronic 
respiratory disease, 4 (14.3%) had diabetes, 3 (10.7%) had 
a chronic cardiac, liver, or neurologic condition, 2 (8.0%) 
were morbidly obese, and 1 (4.0%) had chronic renal 
disease (Table 1). All but 2 of the 21 immunosuppressed 
patients had a hematologic cancer, and 8 of them had 
undergone hematopoietic cell transplantation (Table 2).
Eleven of 30 case-patients (36.7%), ranging in age 
from 2 to 77 years (median 61 years, mean 51 years), have 
died; 7 of the 11 patients had a hematologic cancer, and the 
other 4 had multiple chronic diseases. For 6 patients, death 
was attributed to pneumonia; 2 had septicemia, and 3 had 
multiple organ failure.
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Table 1. Distribution and reported associations of age, sex, and underlying medical conditions of study case-patients and controls
hospitalized for pandemic (H1N1) 2009, England and Scotland, April 27, 2009–April, 30, 2010* 
Patient characteristic
No. (%) case-patients, n = 34 No. (%) controls, n = 346  OR (95% CI) 
n With characteristic n With characteristic Crude  Adjusted†
Sex 
  M  34 23 (67.6)  346 155 (44.8)  0.4 (0.2–0.9)  0.4 (0.2–1.2) 
  F  34 11 (32.4)  346 191 (55.2) 
Age group, y 
  0–4  34 4 (11.8)  346 64 (18.5)  1 1
  5–14  34 4 (11.8)  346 83 (23.9)  0.8 (0.2–3.2)  0.5 (0.1–3.4) 
  15–24  34 1 (2.9)  346 59 (17.1)  0.3 (0.1–2.5)  1
  25–44  34 4 (11.8)  346 74 (21.4)  0.9 (0.2–3.6)  0.5 (0.1–3.6) 
  45–64  34 16 (47.1)  346 56 (16.2)  4.6 (1.4–14.5)  2.4 (0.5–11.1) 
 > 65 34 5 (14.7)  346 10 (2.9)  8.0 (1.8–34.9)  4.1 (0.5–31.3) 
Any underlying condition  30 28 (93.3)  278 164 (60.0)  9.7(2.4–85.5) 
  Respiratory  28 7 (25.0)  284 94 (33.1)  0.8 (0.3–2.1) 
  Cardiac  28 3 (10.7)  273 12 (4.4)  3.0 (0.5–12.1) 
  Renal  28 1 (3.6)  275 11 (4.0)  1.0 (0.0–7.4) 
  Liver  28 3 (10.7)  272 3 (1.1)  12.2 (1.5–95.0) 
  Neurologic  28 3 (10.7)  269 15 (5.6)  2.3 (0.4–9.1) 
  Immunosuppression  28 21 (75.0)  275 19 (6.9)  35.4 (12.7–102.1)  18.1 (6.6–49.9)
  Diabetes  28 4 (14.3)  276 6 (2.2)  9.0 (1.7–41.0) 
 Pregnancy  28 0 301 19  (6.3) 
  Other chronic disease  28 6 (21.4)  258 32 (12.4)  2.5 (0.7–7.2) 
*Case-patients were those with osteltamivir-resistant pandemic (H1N1) 2009 strains; controls were those with osteltamir-sensitive pandemic (H1N1) 2009 
strains. n indicates no. patients with information available for that category. OR, odds ratio; CI, confidence interval.  
†OR adjusted for age, sex, and underlying conditions (e.g., immunosuppression, chronic respiratory diseases). 
Table 2. Type of immunosuppression, presence of hematopoietic cell transplant, and outcomes for patients with oseltamivir-resistant
pandemic (H1N1) 2009, England and Scotland, April 2009–April 30, 2010* 
Type of immunosuppression 
No. with oseltamivir-
resistant strains 
No. with hematopoietic 
cell transplant 
No. admitted to 
ICU No. deaths 
Leukemia
  Acute lymphocytic   2 1
 Acute  myeloid  3 2 1 1
 Chronic  lymphocytic  5 2 2 2
 No  precision  1
Lymphoma 
 Non-Hodgkin  2 1 1 1
 Marginal  zone  1
 Mantle  cell  2 1
Multiple myeloma  1 1 1
Aplastic anemia  1 1
Hematologic cancer with no precision  1 1
TRAPS 1
HIV 1 1
Total 21 8 5 7
*ICU, intensive care unit; TRAPS, tumor necrosis factor receptor–associated periodic syndrome. Oseltamivir-Resistant Pandemic (H1N1) 2009
Information on antiviral treatment was available for 
33/34 (97.1%) case-patients. In specimens from 31 of the 33 
(93.9%) case-patients, collected after antiviral treatment, an 
oseltamivir-resistant strain was detected. A pretreatment, 
oseltamivir-sensitive specimen was available for 22 of these 
case-patients. For the remaining 2 case-patients, ages 5–9 
years, neither a history of antiviral pretreatment nor contact 
with a case of inﬂ  uenza-like-illness could be found. Both 
patients were immunocompromised and had inﬂ  uenza-
like illness symptoms 2–4 weeks before specimens were 
collected. Both patients recovered fully.
Risk Factors for Antiviral Resistance
The 346 controls with oseltamivir-sensitive strains 
ranged in age from 0 to 103 years (median 19, mean 24); 155 
patients (44.8%) were male, and 191 (55.2%) were female 
(Table 3). Of these controls, 58.9% had >1 underlying 
medical condition. A chronic respiratory disease was the 
most common underlying condition (33.1%), and 6.9% of 
controls were immunosuppressed (Table 3). Of the 364 
control patients, 67 (19.4%) had a respiratory complication. 
Of 205 controls for which information was available, 59 
(28.8%) were admitted to ICU; of 322 controls for which 
information was available, 18 (5.6%) died (Table 3).
Controls with oseltamivir-sensitive strains did not differ 
signiﬁ  cantly by age and sex from the hospitalized pandemic 
(H1N1) 2009 patients not tested for antiviral susceptibility 
(Table 3). The proportion of controls with an underlying 
disease, as well as those who were immunosuppressed, 
was lower compared with patients not tested for resistance 
(Table 3). Other underlying diseases were distributed 
equally between these 2 groups. Our reference group of 
patients with oseltamivir-sensitive infections, although 
not randomly selected, thus appears to be representative 
of patients hospitalized with pandemic (H1N1) 2009 
virus infection and, thus, reliable for assessing risk factors 
associated with the development of an oseltamivir-resistant 
virus among persons hospitalized with pandemic (H1N1) 
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Table 3. Distribution of age, sex, underlying medical conditions, and outcomes among persons hospitalized for oseltamivir-sensitive
pandemic (H1N1) 2009 and persons hospitalized for the disease but not tested for antiviral susceptibility, England and Scotland, April 
27, 2009–April 30, 2010* 
Characteristic
No. (%) patients with oseltamivir-
sensitive strains, n = 346 
No. (%) patients not tested for 
antiviral susceptibility, n = 2,471 
F
2 p value  n With characteristic  n With characteristic 
Sex
  M  346 155 (44.8)  2,471  1,176 (47.6)  0.95 0.33
  F  346 191 (55.2)  2,471  1295 (52.4) 
Age group, y
  0–4  346 64 (18.5)  2,471  479 (19.4) 
  5–14  346 83 (24.0)  2,471  463 (18.7)  2.72 0.099 
  15–24  346 59 (17.1)  2,471  406 (16.4)  0.19 0.663 
  25–44  346 74 (21.4)  2,471  611 (24.7)  0.29 0.590 
  45–64  346 56 (16.2)  2,471  391 (15.8)  0.13 0.718 
 > 65 346 10 (2.9)  2,471  121 (4.9)  1.86 0.173 
Any predisposing disease  278 164 (59.0)  1,985  1,315 (66.2)  5.67 0.017 
  Respiratory  284 94 (33.1)  2,198  652 (29.7)  1.41 0.235 
  Cardiac  273 12 (4.4)  2,170  107 (4.9)  0.15 0.699 
  Renal  275 11 (4.0)  2,173  69 (3.2)  0.52 0.469 
  Liver  272 3 (1.1)  2,170  23 (1.1)  0.004  1.000† 
  Neurologic  269 15 (5.6)  2,181  135 (6.2)  0.16 0.692 
  Immunosuppression  275 19 (6.9)  1,980  237 (12.0)  6.14 0.013 
  Diabetes  276 6 (2.2)  2,173  104 (4.8)  3.89 0.048 
  Pregnancy  301 19 (6.3)  2,216  171 (7.7)  0.75 0.387 
  Other chronic disease  258 32 (12.4)  1,836  262 (14.3)  0.65 0.419 
Complications 346 76 (22.0)  2,471  392 (15.9)  8.15 0.004 
 Respiratory  346 67(19.4)  2,471  374  (15.1)  4.11 0.043 
 Cardiac  346 2  (0.6)  2,471  0 14.29  0.015† 
  Renal  346 8 (2.3)  2,471  33 (1.3)  2.02 0.155 
 Liver  346 1  (0.3)  2,471  0 7.14 0.123† 
  Neurologic  346 5 (1.4)  2,471  2 (0.08)  22.78  <0.001† 
 Otitis  346 0 2,471  1  (0.04)  0.14 1.000† 
  Other  346 12 (3.5)  2,471  22 (0.9)  16.91  <0.001 
ICU admission  205 59 (28.8)  1,542  258 (16.7)  17.69  <0.001 
Death  322 18 (5.6)  2,253  78 (3.5)  3.55 0.059 
*n indicates no. patients with information available for that category. ICU, intensive care unit. 
†By Fisher exact test. RESEARCH
2009. However, patients with any complication and those 
admitted to ICU were signiﬁ  cantly more likely to be in the 
group tested for antiviral susceptibility (Table 3), meaning 
that this study only allowed an evaluation of the course 
of disease among patients with the most severe pandemic 
(H1N1) 2009 virus infection.
Comparison between the case-patients with 
oseltamivir-resistant virus infections and controls with 
oseltamivir-sensitive infections showed, on crude analysis, 
that resistance was more common among middle-aged and 
elderly men (Table 1). Case-patients were 9× more likely 
than controls to have an underlying medical condition 
(95% CI 2.4–85.5), particularly immunosuppression (crude 
OR 35.4, 95% CI 12.7–102.1). Chronic liver disease and 
diabetes were also signiﬁ  cantly more likely among case-
patients (crude OR 12.2, 95% CI 1.5–95.0) than controls 
(crude OR 9.0, 95% CI 1.7–41.0).
After adjusting for age and sex, which were 
confounders for underlying disease in the stratiﬁ  ed analysis, 
immunosuppression remained the only variable associated 
with development of oseltamivir resistance (adjusted OR 
18.1, 95% CI 6.6–49.9). The proportions of patients with 
oseltamivir-resistant strains (31/33, 94.0%) and controls 
with oseltamivir-sensitive strains (152/170, 89.4%) who 
received antiviral drugs before a specimen was obtained 
were not signiﬁ  cantly different (adjusted OR 1.7, 95% CI 
0.4–6.6).
Risk Factors for Severe Disease
Case-patients with oseltamivir-resistant strains were at 
higher risk than controls with oseltamivir-sensitive strains 
for complications (crude OR 18.6, 95% CI 6.0–76.2), 
particularly for pneumonia and bronchitis (crude OR 15.8, 
95% CI 5.4–55.6) (Table 4). A higher proportion of case-
patients than controls were admitted to ICU (52.0% vs. 
28.8%), although the difference was not signiﬁ  cant.
The proportion of patients who died was 9.8× higher 
(95% CI 3.6–25.4) among case-patients with oseltamivir-
resistant strains than controls (Table 4). However, after 
adjusting for age, sex, immunosuppression, and chronic 
respiratory diseases, we found a signiﬁ  cantly higher risk for 
complications, particularly for respiratory complications 
(OR 6.6, 95% CI 1.8–23.3), remained associated with the 
presence of an oseltamivir-resistant strain (Table 4).
Discussion
This report summarizes the clinical and epidemiologic 
characteristics of one of the largest collections of 
oseltamivir-resistant pandemic (H1N1) 2009 cases 
described in the literature. Most of the 34 case-patients 
hospitalized in England and Scotland during April 27, 
2009–April 30, 2010, with oseltamivir-resistant pandemic 
(H1N1) 2009 were immunocompromised middle aged or 
elderly men. Selective drug pressure in a particular patient 
subgroup seems to have been responsible for development 
of the resistant strain for most case-patients. Furthermore, 
persons with oseltamivir-resistant pandemic (H1N1) 2009 
infection were more likely than those with oseltamivir-
sensitive virus infections to develop complications.
This study has several limitations. First, our reference 
group was a convenience sample of patients hospitalized 
with oseltamivir-sensitive pandemic (H1N1) 2009. 
Underlying medical conditions and severe outcomes are 
more common in hospitalized patients than patients in 
the community; therefore, this reference group will not 
be representative of all pandemic (H1N1) 2009 patients, 
and our results cannot be generalized to community cases. 
Although sporadic (14,23) and clustered (15) cases of 
oseltamivir resistance have been reported in communities 
in several countries, the World Health Organization has not 
reported widespread community circulation of oseltamivir-
resistant pandemic (H1N1) 2009 virus (24). In the United 
Kingdom, more than one third of subtype H1N1 specimens 
tested for antiviral susceptibility were from patients from 
the community rather than hospitalized patients. However, 
only 2 of 45 patients (4.4%) with oseltamivir-resistant virus 
were from the community, and both cases were treatment 
induced. The recommendations for antiviral susceptibility 
testing introduced a second selection bias in this study. 
Our reference group was found to be representative of 
patients hospitalized with pandemic (H1N1) 2009 in terms 
of age and sex. However, the proportion of patients with 
underlying disease and immunosuppression was lower in 
the tested controls than in the nontested group. This ﬁ  nding 
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Table 4. Distribution and reported associations of outcomes (complications, ICU admission, death) for study patients and controls
hospitalized for pandemic (H1N1) 2009, England and Scotland, April 27, 2009–April, 30, 2010* 
Outcome
Case-patients with oseltamivir-
resistant strains, n = 34 
Controls with oseltamivir-
sensitive strains, n = 346  OR (95% CI) 
n No. (%) with outcome  n No. (%) with outcome  Crude  Adjusted†
Any complications  25 21 (84.0)  346 76 (22.0)  18.6 (6.0–76.2)  9.0 (2.4–34.3) 
Respiratory complications  24 19 (79.2)  346 67 (19.4)  15.8 (5.4–55.6)  6.6 (1.8–23.3) 
ICU admission  23 12 (52.01)  205 59 (28.8)  2.3 (1.0–7.1)  2.3 (0.7–7.9) 
Death  30 11 (36.7)  322 18 (5.6)  9.8 (3.6–25.4)  2.2 (0.5–9.5) 
*n indicates no. patients with information available for that category. ICU, intensive care unit, OR, odds ratio; CI, confidence interval. 
†OR adjusted for age, sex, and underlying conditions (e.g., immunosuppression, chronic respiratory diseases). Oseltamivir-Resistant Pandemic (H1N1) 2009
may have led to a slight overestimation of the size of the 
association between these risk factors and the development 
of oseltamivir-resistant virus.
In addition, patients who had any complication 
and those admitted to ICU were overrepresented in our 
reference group, meaning that the course of the disease was 
studied among the patients with the most severe concurrent 
conditions who were hospitalized with pandemic (H1N1) 
2009. In addition, because the number of diagnosed cases 
of oseltamivir-resistant pandemic (H1N1) 2009 virus 
infection remains limited, any associations should be 
interpreted carefully. Last, although information on the 
case-patients with oseltamivir-resistant strains was actively 
collected, information for the controls with oseltamivir-
sensitive strains was voluntarily reported by hospital 
microbiologists and was therefore subject to potential 
reporting bias.
In contrast to ﬁ  ndings for seasonal inﬂ  uenza, the initial 
epidemiologic ﬁ  ndings of pandemic (H1N1) 2009 in the 
United Kingdom were that persons <24 years of age were 
more likely to become infected than persons >65 years of 
age (25). However, in our study, >60% of the infections 
with oseltamivir-resistant viruses occurred in persons >45 
years of age. The high proportion of immunocompromised 
persons among the resistant cases presumably explains this 
age difference. In a study done in the United Kingdom, 
the prevalence of immunocompromised patients increased 
with age, from 1.5% in children and young adults >7% in 
persons >70 years of age (26).
In this report, 93.5% of the resistant case-patients 
and 58.9% of the susceptible controls had >1 underlying 
medical condition. In several other countries, the presence 
of >1 risk factor was associated with an increased risk 
for hospitalization (25,27). As in patients with seasonal 
inﬂ   uenza, chronic respiratory disease was the most 
commonly reported underlying medical condition for 
control patients infected with a susceptible virus. However, 
70% of the resistant case-patients were immunosuppressed, 
and immunosuppression was the only independent 
variable associated with the presence of an oseltamivir-
resistant virus, with most of the case-patients having 
received oseltamivir therapy before being diagnosed with 
a resistant strain. These results are consistent with several 
other reports in which resistance seemed to develop more 
frequently among severely immunosuppressed patients 
treated with antiviral drugs (24,28–30). Prolonged virus 
shedding in the setting of antiviral therapy is known to 
lead to increased risk for the emergence of oseltamivir-
resistant seasonal inﬂ   uenza viruses (6). Instances of 
immunosuppressed patients with prolonged virus shedding 
have been documented for oseltamivir-resistant seasonal 
and pandemic (H1N1) 2009 inﬂ   uenza viruses (31). In 
addition, prophylaxis and treatment were recommended 
for immunocompromised patients during the 2009–10 
inﬂ  uenza pandemic.
The clinical features of case-patients infected with 
oseltamivir-resistant pandemic (H1N1) 2009 virus 
were similar to those previously described for patients 
hospitalized during the pandemic (25,27): fever and cough 
were the most common symptoms, and ≈30% of the case-
patients had gastrointestinal symptoms. Of note, dyspnea 
was present in 55% of case-patients, which may suggest 
an early lower respiratory tract infection in these patients. 
In this study, pneumonia was the main complication 
reported for patients with oseltamivir-resistant strains 
and those with oseltamivir-sensitive strains. Pneumonia 
is a usual complication of seasonal inﬂ  uenza, particularly 
among immunocompromised patients (32). A signiﬁ  cant 
proportion of patients hospitalized with pandemic (H1N1) 
2009 were also reported with pneumonia (27,29,33). The 
ability of the pandemic (H1N1) 2009 virus to replicate in 
the lungs, as shown in animal models (34), may explain 
the high frequency of this complication in the 2009–10 
pandemic. Although the risk for such complications 
developing was signiﬁ   cantly higher among patients 
with oseltamivir-resistant strains, this result should be 
interpreted carefully as no information regarding either 
a possible bacterial co-infection or the time of sampling 
during the course of illness was available.
Half of the patients infected with an oseltamivir-
resistant virus were admitted to the ICU, and approximately 
one third died. Although the risk for developing more severe 
outcomes appeared higher among patients with oseltamivir-
resistant strains, the multivariate analysis indicated that the 
presence of an underlying medical condition, especially 
immunosuppression or chronic respiratory disease, 
played a more important role in the development of such 
severe outcomes. In other studies (27,35–37), underlying 
concurrent conditions correlated with a high risk for ICU 
admission and death. Immunosuppression has already been 
described as an important risk factor for ICU admission 
and death during seasonal inﬂ  uenza outbreaks (38). A more 
severe outcome of pandemic (H1N1) 2009 virus infection 
among immunocompromised persons was also reported in 
several studies (27,29,30,37,39).
In conclusion, clinicians should be aware of the 
emergence of oseltamivir-resistant pandemic (H1N1) 
2009 virus, particularly in immunosuppressed patients. 
Testing for antiviral resistance is needed, especially among 
this group, to ensure appropriate antiviral prescribing, 
minimize the risk for treatment failure, and minimize the 
risk of person-to-person transmission of a resistant strain. 
Although the selective pressure of treatment seems to be 
the most likely mechanism to explain the development of 
resistant strains, person-to-person transmission has also 
been demonstrated. To limit the potential for secondary 
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transmission of resistant virus, it is recommended that 
clinicians check for virus clearance at the end of treatment. 
Changes in the recommendations of antiviral drug use for 
immunocompromised patients are already implemented 
in the United Kingdom. Either zanamivir as monotherapy 
or oseltamivir combined with zanamivir should be 
offered as primary treatment for all immunocompromised 
patients. Although the immune response to vaccine can 
be lower in some persons, particularly those who are 
immunosuppressed, inﬂ   uenza vaccination remains the 
major intervention to protect immunosuppressed patients 
who are at risk for the development of more severe disease. 
Dr Calatayud is a trainee of the European Programme for 
Intervention Epidemiology Training at the Health Protection 
Agency, Centre for Infections, London, UK. Her main research 
interests involve respiratory infections.
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From the Greek, plasma, anything formed or molded, and Robert Knowles, a physician with the Indian Medi-
cal Service, credited with discovery of the organism. Knowles himself attributed the ﬁ  nding of P. knowlesi to 2 
colleagues (L.E. Napier and H.G.M. Campbell) at the School of Tropical Medicine and Hygiene in Calcutta who 
found the protozoan while investigating kala-azar transmission. “Knowing that we should be interested in the strain 
from a protozoological point of view,” Knowles wrote, “[Napier] handed over the original monkey to my assistant, 
Dr. B.M. Das Gupta.” Das Gupta maintained the strain in monkeys until he and Knowles were able to carry out 
human infection experiments, which they reported in 1932.
Sources:  Centers for Disease Control and Prevention. The history of malaria, an ancient disease [cited 2011 Jul 22]. http://
www.cdc.gov/malaria/about/history; Dorland’s illustrated medical dictionary. 31st ed. Philadelphia: Saunders; 2007; Knowles R. 
Monkey malaria. BMJ. 1935;2:1020. doi:10.1136/bmj.2.3907.1020; Knowles R, Das Gupta BM. A study of monkey-malaria, and 
its experimental transmission to man. Ind Med Gaz. 1932;67:301–21. 
Edited by Nancy Männikkö; email: nmannikko@cdc.gov
DOI: http://dx.doi.org/10.3201/eid1710.ET1710 